HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (the “Company”) today announced that the Company’s Board of Directors has approved a 1 for 12.62 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock“). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in connection with the reverse stock split.

On December 30, 2025, the Company’s stockholders approved a second reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-12.48 and not more than 1-for-50 to be implemented at the discretion of the Chief Executive Officer. The Reverse Stock Split is intended to support the Company’s efforts in connection with the proposed business-combination transaction and its continued-listing objectives. The Reverse Stock Split does not assure that the Company will satisfy applicable NYSE American continued-listing standards, obtain approval of any applicable listing application, or complete the proposed transaction.

The merger of Impact BioMedical Inc. and Zoar Ltd, upon approval, will result in a new company with manufacturing and clinical development expertise across a broad spectrum of active pharmaceutical ingredients (API’s) and intermediates for life-saving drugs worldwide, with immediate focus on emerging markets. It will also include significant intellectual property with potential in human health and wellness markets.

( Read the original merger announcement here.).  

Upon completion of the proposed merger, Impact stockholders are expected to receive one (1) share of Zoar Ltd. for every four (4) shares of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split.

The reverse stock split will combine every 12.62 shares of the Company’s issued and outstanding Common Stock into one (1) new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will have their fractional share rounded up to the next whole share. Other than adjustments resulting from the treatment of fractional shares, the Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company.

Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take any action. Impact BioMedical’s transfer agent, Equiniti Trust Company, LLC (“Equiniti”), will manage the exchange. Stockholders of record who hold physical certificates will receive a letter of transmittal from Equiniti with instructions for exchanging their shares. Unless a stockholder specifically requests new paper certificates (or holds restricted shares), new shares will be issued electronically in book-entry form.

Following the reverse stock split, the total number of shares of Common Stock outstanding is expected to decrease from approximately 107,821,231 to 8,543,679 subject to minor adjustments due to rounding. Corresponding proportional adjustments will also be made to:

  • Outstanding equity awards and related exercise prices
  • Shares available under equity incentive plans
  • Other relevant share-based agreements

The reverse stock split will not affect the total number of authorized shares, and all resulting shares will remain fully paid and non-assessable.

Additional information about the reverse stock split can be found in the Company’s definitive information statement filed with the Securities and Exchange Commission (the “SEC“) on December 30, 2025, which is available free of charge at the SEC’s website, www.sec.gov.

About Zoar Ltd.
Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.

About IBO:
Impact BioMedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com

CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to three newly hired employees.

Korro granted the new employees nonstatutory stock options to purchase 5,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $12.93 per share, the closing price per share of Korro’s common stock as reported by Nasdaq on the grant effective date, September 9, 2026. The options each have a ten-year term and vest over four years, with 25% of the shares vesting on the first anniversary of each such employee’s applicable start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of such employee’s applicable start date, subject to the employee’s continued service with Korro through each applicable vesting date.

These grants were approved by Korro’s independent Compensation Committee pursuant to Korro’s 2026 Inducement Plan and were made as an inducement material to the employee’s acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4).

About Korro

Korro is a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Bio Contact Information

Investor & Media Contact 
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269

Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT

NORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.D., an investigator for the study, will be a guest speaker in the event. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management and a new therapeutic option for obesity beyond GLP-1 and other incretin-targeting therapies.

The CANYON-1 Phase 1b clinical trial is a 16-week double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adult participants conducted at multiple clinical sites in the United States (NCT07310901). The trial includes three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily (QD) as well as a placebo cohort (randomization of 1:1:1:1). A dose titration regimen was included in the design, with all participants receiving CRB-913 commencing at 20 mg/day and then titrating up to either 40 mg/day or beyond that to 60 mg/day, depending on their assigned cohorts. Participants were dosed for 12 weeks followed by a four-week safety follow-up.

Registration Details
 
Date: Monday, September 14, 2026
   
Time: 8:00 a.m. EDT
   
Registration: Click here
   
A replay will be available on the Corbus website following the event.
 

About Harold Bays, M.D.

Dr. Harold Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Obesity Medicine and Diplomate of the American Board of Clinical Lipidology. He is Medical Director Louisville Metabolic and Atherosclerosis Research Center/ Monroe Biomedical Research and Clinical Associate Professor at the University of Louisville School of Medicine. He has served as an Investigator for over 700 Phase I – IV clinical trials regarding treatments for obesity, dyslipidemias, diabetes mellitus, hypertension, and other cardiometabolic and hormonal disorders. Dr. Bays is Chief Science Officer of the Obesity Medicine Association and is Editor in Chief for Obesity Pillars – the journal of the Obesity Medicine Association. Dr. Bays was President of the Obesity Medicine Association in 2025 – 2026. Dr. Bays has written and/or served as a contributing author for approximately 400 peer review scientific manuscripts and book chapters, hundreds of scientific abstracts presented at major scientific meetings. He has served as first author and/or co-author for scientific consensus statements, position statements, and clinical practice statements in Obesity Medicine and Clinical Lipidology. He is a Fellow of the Obesity Medicine Association (FOMA), Fellow of the National Lipid Association (FNLA), Fellow of The Obesity Society (FTOS), Fellow of the American College of Cardiology (FACC), and Fellow of the American Society of Preventive Cardiology (FASPC). Dr. Bays originated the term “adiposopathy” (“sick fat”), which defines how and when the pathogenic consequences of adipose tissue accumulation promote metabolic disease, including dyslipidemia, diabetes mellitus, and hypertension. Dr. Bays has received several scientific awards in such as the 2016 Obesity Medicine Association “Obesity Medicine Association Clinician of the Year,” 2026 Obesity Medicine Association Research Award, and 2015 National Lipid Association “President’s Service Award.” Finally, in 2026, Clarivate designated Dr. Bays as a “Highly Cited Researcher,” defined as having authored “multiple Highly Cited Papers that rank in the top 1% by citations for their field(s) and publication year in the Web of Science Core Collection – indicating exceptional influence in their respective disciplines.”

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated timing for initiation of clinical trials, anticipated regulatory interactions and outcomes, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

SPRINGFIELD, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Village Super Market, Inc. (NSD:VLGEA) declared quarterly cash dividends of $0.25 per Class A common share and $0.1625 per Class B common share. The dividends will be payable on October 22, 2026 to shareholders of record at the close of business on October 1, 2026.

Village Super Market operates a chain of 34 supermarkets in New Jersey, New York, Maryland and Pennsylvania under the ShopRite and Fairway banners and three Gourmet Garage specialty markets in New York City.

Contact: John Van Orden, CFO
  (973) 467-2200
  VillageInvestorRelations@wakefern.com

CALGARY, Alberta, Sept. 11, 2026 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE) (TSX:GTE) (LSE: GTE) today announced that it is conducting a solicitation (the “Consent Solicitation”) of consents (the “Consents”) from Holders of its 9.750% Senior Secured Amortizing Notes due 2031 (the “Notes”) to effect certain proposed amendments (the “Proposed Amendments”) to the indenture dated as of February 18, 2026, under which the Notes were issued (the “Indenture”), pursuant to the terms and subject to the conditions set forth in the Consent Solicitation Statement, dated September 11, 2026 (the “Consent Solicitation Statement”). Any capitalized terms used in this press release without definition have the respective meanings assigned to such terms in the Consent Solicitation Statement.

Notes CUSIP/ISIN Numbers Principal Amount
Outstanding
Consent Fee
9.750% Senior Secured
Amortizing Notes due
2031
Rule 144A: 38500T AD3 / US38500TAD37
Regulation S: U37016 AF6 / USU37016AF67
US$479,353,000 US$2.50 per US$1,000

As previously announced, on August 5, 2026, the Company entered into a Share Sale and Purchase Agreement (as it may be amended from time to time in accordance with its terms, the “Share Purchase Agreement”) with Établissements Maurel et Prom S.A., a company organized and existing under the laws of France (“M&P”), Maurel & Prom Andina S.A.S., a company organized and existing under the laws of France and an indirect wholly owned subsidiary of M&P (“Purchaser”), and the other parties thereto, whereby, among other things, Gran Tierra Energy International Holdings GmbH, a company organized and existing under the laws of Switzerland and an indirect wholly owned subsidiary of the Company, has agreed to sell all of the issued and outstanding equity interests of Gran Tierra Energy CI GmbH, a company organized and existing under the laws of Switzerland and an indirect wholly owned subsidiary of the Company (“GTECI”), to Purchaser (the transactions contemplated by the Share Purchase Agreement, the “Sale”). At Completion (as defined in the Share Purchase Agreement), among other things, Purchaser will assume the performance of every covenant and all obligations of the Company under the Indenture, the Notes, and the applicable collateral documents (to the extent not released) (the “Note Assumption”).

The Proposed Amendments would (i) enable the Note Assumption by releasing certain collateral, waiving debt coverage tests related to successor issuers for purposes of the Sale and providing that the Sale is not a Change of Control under the Indenture, (ii) update the definition of “GAAP” in the Indenture to include International Financial Reporting Standards as issued and interpreted by the International Accounting Standards Board and accounting principles that are recognized as being generally accepted in France, (iii) update the financial reporting covenant, including to reflect that neither M&P nor Purchaser is an SEC-reporting company and to permit the reporting of hydrocarbon proved reserve information pursuant to the Petroleum Resources Management System of the Society of Petroleum Engineers, and (iv) provide that certain acquisitions of working interests in the Sinu-9 gas license in Colombia by Purchaser or any Restricted Subsidiary (as defined in the Indenture) from certain affiliates of M&P will be considered a “Permitted Investment” under the Indenture. No other changes will be made to the Indenture or the Notes. The interest rate, payment terms, and maturity date of the Notes will remain the same, and the Notes will remain secured by a first-ranking pledge by GTECI in respect of all of the quotas and other equity securities of any kind of Gran Tierra Energy Colombia GmbH and Gran Tierra Operations Colombia GmbH.

The Proposed Amendments must be consented to by Holders of not less than 50% in aggregate principal amount of the Notes outstanding (the “Requisite Consents”) in order to be effective.

Subject to the terms and conditions of this Consent Solicitation Statement, the Company is offering Holders of Notes who validly deliver (and do not validly revoke) their consents prior to the Expiration Time (as defined below) (each such Holder a “Consenting Holder”) consent consideration equal to US$2.50 per US$1,000 in principal amount of Notes held by such Consenting Holder (the “Consent Fee”) payable on the closing date of the Sale.

Consummation of the Consent Solicitation and payment of the Consent Fee are conditioned upon the satisfaction or waiver of the conditions described in the Consent Solicitation Statement, including, among other things, obtaining the Requisite Consents and the completion of the Sale. If the Requisite Consents have not been obtained by the Expiration Time (as defined below), the Company may, in its discretion and without limitation, extend the Consent Solicitation in order to seek to obtain the Requisite Consents or cause the other conditions to the Consent Solicitation to be satisfied.

Holders of the Notes must validly deliver their Consents at or prior to 5:00 p.m., New York City time, on September 22, 2026, unless extended or earlier terminated by the Company, in its sole discretion (such date and time, as the same may be extended or earlier terminated, the “Expiration Time”). A Holder may validly revoke its Consent prior to the earlier of the Expiration Time and the time of execution of the Supplemental Indenture (such date and time, as the same may be extended, the “Withdrawal Deadline”). Holders who deliver their Consents at or prior to the Expiration Time (and do not validly revoke such Consents at or before the Withdrawal Deadline) will be eligible to receive the Consent Fee.

If the Requisite Consents are received, it is expected that a Supplemental Indenture setting forth the Proposed Amendments will be entered into by the Company, the Note Guarantors and the Trustee promptly after receipt of such Requisite Consents, whether before or after the Expiration Time. The Supplemental Indenture will give effect to the Proposed Amendments and will be effective upon execution, but will only become operative on the closing date of the Sale.

The Company reserves the right to modify the Consent Solicitation Statement and the terms and conditions of the Consent Solicitation or to terminate the Consent Solicitation.

BofA Securities, Inc. is serving as sole Solicitation Agent in the Consent Solicitation and D.F. King & Co. Inc. has been retained to serve as the Information and Tabulation Agent. Persons with questions regarding the Consent Solicitation should contact BofA Securities, Inc. at (toll free) (888) 292-0070 or (collect) (646) 855-8988. Requests for the Consent Solicitation Statement should be directed to D.F. King & Co. Inc., at (toll free) (888) 548-6498, (banks and brokers) (646) 582-9168 or by email to gte@dfking.com.

None of the Company, the Solicitation Agent, the Trustee under the Indenture, or the Information and Tabulation Agent makes any recommendation as to whether or not Holders should deliver Consents in the Consent Solicitation.

This press release is not a solicitation of consents with respect to the Proposed Amendments or otherwise. The Consent Solicitation is being made solely through the Consent Solicitation Statement referred to above and related materials. The Consent Solicitation is not being made to Holders of Notes in any jurisdiction where the making of the Consent Solicitation would not be in compliance with the laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Consent Solicitation to be made by a licensed broker or dealer, the Consent Solicitation will be deemed to be made on the Company’s behalf by the Solicitation Agent or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction. Neither the Consent Solicitation Statement nor any documents related to the Consent Solicitation have been filed with, or approved or reviewed by, any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Consent Solicitation Statement or any documents related to the Consent Solicitation, and it is unlawful and may be a criminal offense to make any representation to the contrary.

Contact Information

For investor and media inquiries please contact:
Gary Guidry, Chief Executive Officer
Ryan Ellson, Executive Vice President & Chief Financial Officer
+1-403-265-3221
info@grantierra.com

About Gran Tierra Energy Inc.

Gran Tierra Energy Inc., together with its subsidiaries, is an independent international energy company currently focused on oil and natural gas exploration and production in Canada, Colombia, Ecuador and Azerbaijan. Upon completion of the Sale described in this press release, the Company’s producing operations will be focused on Canada, and the Company will continue to pursue its exploration interests in Azerbaijan and additional new growth opportunities that would further strengthen the Company’s portfolio. The Company’s common stock trades on the NYSE American, the Toronto Stock Exchange and the London Stock Exchange under the ticker symbol GTE. Additional information concerning Gran Tierra is available at www.grantierra.com. Except to the extent expressly stated otherwise, information on the Company’s website or accessible from our website or any other website is not incorporated by reference into and should not be considered part of this press release. Investor inquiries may be directed to info@grantierra.com or (403) 265-3221.

Gran Tierra’s filings with the U.S. Securities and Exchange Commission (the “SEC”) are available on the SEC website at http://www.sec.gov. Gran Tierra’s Canadian securities regulatory filings are available on SEDAR+ at http://www.sedarplus.ca and UK regulatory filings are available on the National Storage Mechanism website at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Forward Looking Statements and Legal Advisories:

This press release contains opinions, forecasts, projections, and other statements about future events or results that constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and financial outlook and forward looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”), which can be identified by such terms as “expect,” “plan,” “can,” “will,” “should,” “guidance,” “estimate,” “forecast,” “intend,” “anticipate,” “believes,” and “remains subject to,” derivations thereof and similar terms are intended to identify forward-looking statements. Such forward-looking statements include, but are not limited to, the form and results of the Consent Solicitation; the Company’s ability to obtain amendments to the Indenture; statements regarding the anticipated benefits of the Sale; the satisfaction of the conditions precedent to, and the timing of the completion of, the Sale; the receipt of the Requisite Consents of the Holders; the expected closing date of the Sale; the Note Assumption and the related reduction of the Company’s net debt; the Company’s strategy and growth plans in Canada and Azerbaijan.

The forward-looking statements contained in this press release are based on certain assumptions made by Gran Tierra based on management’s experience and other factors believed to be appropriate. Gran Tierra believes these assumptions to be reasonable at this time, but the forward-looking statements are subject to risks and uncertainties, many of which are beyond Gran Tierra’s control, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. All forward-looking statements are made as of the date of this press release and the fact that this press release remains available does not constitute a representation by Gran Tierra that Gran Tierra believes these forward-looking statements continue to be true as of any subsequent date. Actual results may vary materially from the expected results expressed in forward-looking statements. Gran Tierra disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Important Information Regarding the Sale

This press release is neither a solicitation of a proxy nor an offer to purchase nor a solicitation of an offer to sell any securities. This press release is also not a substitute for any proxy statement or other filings that may be made with the SEC with respect to the Sale. Approval of the Sale will be submitted to the Company’s stockholders for their consideration. The Company has filed a preliminary proxy statement with the SEC and will file a definitive proxy statement to be used to solicit stockholder approval of the transaction. Detailed information about the Sale is contained in the preliminary proxy statement and will be contained in the definitive proxy statement and other documents to be filed with the SEC and disseminated to stockholders prior to the meeting.

NEWPORT NEWS, Va., Sept. 11, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that it has been awarded a contract from the U.S. Navy to start procurement of long-lead time materials (LLTM) for the construction of planned aircraft carrier CVN 82 at its Newport News Shipbuilding division.

The $336 million undefinitized contract award will initiate advanced procurement of propulsion plant materials critical to the future construction of CVN 82.

“Ordering the materials necessary to build the world’s mightiest aircraft carriers is a critical first step as we begin planning for CVN 82,” said Bryan Caccavale, NNS vice president of program management. “This contract sends an important demand signal to the thousands of suppliers across the nation who make up the aircraft carrier industrial base.”

CVN 82 will continue the legacy of highly capable nuclear-powered U.S. aircraft carriers.

DCS20-473-120

A photo accompanying this release is available at: http://hii.com/news/hii-is-awarded-long-lead-time-materials-contract-for-cvn-82/.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

Contact:

Todd Corillo
Todd.T.Corillo@HII-co.com
(757) 688-3220

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/995ce200-f9d6-440a-be87-da8cc1e255c9

PALOS VERDES ESTATES, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Malaga Financial Corporation (OTCIQ:MLGF) announced today the declaration of a cash dividend in the amount of 25 cents per share to shareholders of record on September 23, 2026. The dividend will be paid out on or about October 1, 2026. Randy C. Bowers, Chairman, President and CEO, remarked, “We are pleased to reward our loyal shareholders with this 25-cent quarterly dividend which represents a 4.45% annualized yield based on our most recent closing price of $22.46. We are grateful for the efforts of our colleagues which has positioned us to declare this 89th consecutive quarterly cash dividend.”

Malaga Bank, a subsidiary of Malaga Financial Corporation, is a full-service community bank headquartered on the Palos Verdes Peninsula with six offices located in the South Bay area of Los Angeles. For over eighteen years Malaga Bank has been consistently recommended by one of the nation’s leading independent bank rating and research firms, Bauer Financial Inc. Malaga Bank was awarded Bauer’s premier Top 5-Star rating for the 75th consecutive quarter as of June 2026. Since 1985, Malaga Bank has been delivering competitive consecutive banking services to residents and businesses of the South Bay, including real estate loan products custom-tailored to consumers and investors. As the largest community bank in the South Bay, Malaga is proud of its continuing tradition of relationship-based banking and legendary customer service. The Bank’s web site is located at www.malagabank.com.

Contact: Randy Bowers
Chairman, President and Chief Executive Officer
Malaga Financial Corporation
(310) 375-9000
rbowers@malagabank.com
   

  • FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg
  • Newly approved Joenja doses are expected to be available in October

Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. With this approval, Joenja becomes the first FDA-approved treatment for children aged 4 to 11 years with APDS in the U.S. The newly approved Joenja doses are expected to be available to eligible pediatric patients in the U.S. in October through Pharming’s established specialty distribution network and patient-support infrastructure.

On July 30, Pharming also submitted a separate sNDA seeking approval of lower Joenja doses for pediatric APDS patients aged 4 to11 years who weigh 13 kg to less than 27 kg.

“To give children living with APDS the best chance at a healthier future, early disease intervention is critical,” commented Eveline Wu, M.D., MSCR, Associate Professor of Pediatrics at the University of North Carolina at Chapel Hill. “Previously, our best approach for children aged 4 to 11 years with APDS was to provide an accurate diagnosis and a treatment plan to manage the symptoms of APDS. With the approval of Joenja for this pediatric population, we can now take that support even further to address the underlying pathway of disease, with the goal of reducing symptoms and preventing the irreversible complications that often arise with APDS.”

“APDS is not a disease that waits. It can affect important aspects of childhood, potentially impacting time in school, time with friends, and other activities of daily life. This approval is a meaningful step forward because it gives younger patients and their physicians another much-needed option earlier in the disease journey,” said Vanessa Tenembaum, CEO of the Jeffrey Modell Foundation, an international, non-profit, organization dedicated to helping individuals and family members affected by primary immunodeficiency disorders. “For families living with APDS, it means more than progress; it means renewed hope, greater possibility and a clearer path forward.”

APDS typically manifests in early childhood and is characterized by significant immune dysregulation and recurrent sinopulmonary infections, which over time can lead to permanent lung damage and other serious complications. For children living with APDS, the burden can extend beyond clinical symptoms. Recurrent infections, medical appointments and treatment demands may disrupt school attendance, learning and social development, adding to the daily impact on patients and families.

“Today’s approval marks an important achievement in our efforts to expand the availability of Joenja to more individuals living with APDS. We are grateful to the FDA, trial participants, caregivers, investigators, healthcare providers and the APDS community whose partnership helped make this milestone possible,” said Leverne Marsh, Chief Commercial Officer of Pharming. “Our immediate priority is to support physicians and families in navigating the access pathway so treatment can start as quickly and responsibly as possible.”

Joenja received approval from the U.S. FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023. Today’s approval is supported by data from a multinational, open-label, single-arm Phase III study in children aged 4 to 11 years with APDS. The study demonstrated improvements over 12 weeks in two clinically relevant hallmarks of the condition, reduced lymphadenopathy and increased naïve B cells, together indicating an improvement in the underlying immune defect. The safety profile was consistent with prior Joenja experience; all treatment emergent adverse events were mild to moderate in nature, and no drug related serious adverse events were observed.

US Important Safety Information for Joenja® (leniolisib)

INDICATIONS AND USAGE
Joenja® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater.

IMPORTANT SAFETY INFORMATION
Verify pregnancy status in females of reproductive potential prior to initiating treatment with Joenja.

Joenja may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with Joenja and for 1 week after the last dose. Additionally, advise women not to breastfeed during treatment with Joenja and for 1 week after the last dose.

Live, attenuated vaccinations may be less effective if administered during Joenja treatment.

Joenja may cause hypersensitivity reaction(s), including anaphylaxis. Advise patients to discontinue Joenja and to seek immediate medical attention if they develop any signs and symptoms of serious allergic reactions.

Use of Joenja in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients under 4 years of age or weighing less than 27 kg.

Avoid co-administration of Joenja with other medications known to be strong CYP3A4 inhibitors, strong or moderate CYP3A4 inducers, or BCRP, OATP1B1, and OATP1B3 substrates.

Most common adverse reaction (incidence >10%):

  • Adult and pediatric patients 12 years of age and older: headache, sinusitis, atopic dermatitis, and weight gain.
  • Pediatric patients 4 to <12 years of age who weigh 27 kg or greater: abdominal pain, cough, and respiratory tract infection.

Seven (33%) patients 12 years and older (n=21) and 5 (63%) patients 4 to 12 years of age and weighing more than 27 kg or greater (n=8) developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL after receiving Joenja. No patients developed an ANC <500 cells/microL and there were no reports of infection associated with neutropenia.

Before prescribing Joenja, please read the full Prescribing Information.

Joenja is available in 40 mg, 50 mg, and 70 mg tablets.

Based on PI Approved: 09/2026

About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS) 
APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation1,2,3 APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide.8 

About Joenja®
Joenja® (leniolisib) is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved as the first and only treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the U.S., U.K., Australia, Israel, Canada and the European Union in adult and pediatric patients 12 years of age and older and in Japan for patients 4 years of age and older. Joenja® inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and open label extension data has supported the safety and tolerability of long-term leniolisib administration.9,10   
Leniolisib is currently under regulatory review for the treatment of APDS in Canada and several other countries. Leniolisib is also being evaluated in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS.  

About Pharming
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.

We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases. 

Pharming is headquartered in Leiden, the Netherlands, with operations in the United States and Europe. 

For more information, visit www.pharming.com and follow us on LinkedIn. 

Forward-looking Statements
This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

References 

  1. FDA. Priority Review. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review Accessed October 2025.
  2. Lucas CL, et al. Nat Immunol. 2014;15(1):88-97.
  3. Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.
  4. Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.
  5. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.
  6. Maccari ME, et al. Front Immunol. 2018;9:543.
  7. Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333.
  8. Condliffe AM, Chandra A. Front Immunol. 2018;9:338.
  9. Rao VK, et al Blood. 2023 Mar 2;141(9):971-983.
  10. Rao VK, et al.  J Allergy Clin Immunol 2024;153:265-74.

For further public information, contact:
Pharming
Michael Levitan, VP Investor Relations & Capital Markets
T: +1 (908) 705 1696
E: investor@pharming.com

Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

Media Relations
Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)
E:  JDeutsch@lyraadvisory.com

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

Company completes 104.8-ton bulk-sampling program at Skaergaard; advances geological mapping and environmental baseline studies at Sarfartoq

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Sling operation for the opening of the Sarfartoq exploration camp.
Sling operation for the opening of the Sarfartoq exploration camp.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Blasted material being hammered into smaller fragments and loaded in bulk bags.
Blasted material being hammered into smaller fragments and loaded in bulk bags.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

WSP Denmark consultant carrying out environmental base line study work near the ST1 REE mineralized zone at Sarfartoq.
WSP Denmark consultant carrying out environmental base line study work near the ST1 REE mineralized zone at Sarfartoq.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Bulk bags slung to lay-down area at Uttendal Sund at Skaergaard with anchored support vessel Argus in the background.
Bulk bags slung to lay-down area at Uttendal Sund at Skaergaard with anchored support vessel Argus in the background.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Newly installed weather station at Sarfartoq – part of the second year of environmental baseline study. Exploration camp at Sarfartoq in the background.
Newly installed weather station at Sarfartoq – part of the second year of environmental baseline study. Exploration camp at Sarfartoq in the background.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Blasting in one of the gold mineralized zones within the Skaergaard Intrusion. The blasted material will be collected and used for metallurgical and processing flowsheet purposes.
Blasting in one of the gold mineralized zones within the Skaergaard Intrusion. The blasted material will be collected and used for metallurgical and processing flowsheet purposes.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Holes loaded and ready for blasting at Skaergaard 2026.
Holes loaded and ready for blasting at Skaergaard 2026.

CHARLOTTE, N.C., Sept. 11, 2026 (GLOBE NEWSWIRE) — via IBN – Greenland Mines Ltd (Nasdaq: GRML) (“Greenland Mines” or the “Company”) today provided an update on the progress of its 2026 field programs at the Skaergaard palladium-platinum-gold project in East Greenland and the Sarfartoq rare earth element project in West Greenland.

Bo Møller Stensgaard, President of Greenland Mines, commented:
“Our teams have delivered an outstanding field season at both projects. At Skaergaard, we set out to collect representative bulk material from three key horizons and ended up completing seven bulk-sample sites, giving GTK Mintec and our other metallurgical consultants substantially more material and more variability data than originally planned.

“At Sarfartoq, only weeks after closing the acquisition and announcing an Initial Assessment that demonstrated a high-case pre-tax net present value of approximately US$2.05 billion and a pre-tax internal rate of return of 118.6%, we already have boots on the ground running both structural mapping and the second year of environmental baseline studies.

“This is exactly the kind of execution and pace we committed to our shareholders, and it positions both projects well ahead of their next technical milestones.”

Skaergaard: Bulk-Sampling Program Completed, Exceeding Plan

Greenland Mines has completed its 2026 bulk-sample blasting program at Skaergaard, collecting a total of 104.8 tons of mineralized and host material from seven sites — more sites than originally planned for the season. All bulk samples were weighed in the field while being sling-loaded by helicopter to a central lay-down area, with final confirmed weights to follow in the next phase of test work.

The program’s three major bulk-sample sites, yielding approximately 30.4, 28.3 and 30.6 tons of material, were located at the toe area in front of Forbindelsesgletscher, on the eastern shore of Uttentaldal Sund. These sites targeted, respectively, the modelled Palladium-Platinum-dominated mineralized Horizon 0, the Gold-dominated mineralized Horizon 3, and the interstitial vanadium-bearing titanomagnetite (VTM) horizons within the Skaergaard gabbro sequence.

Horizon 0 and Horizon 3 form part of the resource-defining horizon framework established for the Skaergaard Mineral Resource Estimate, with Horizon 0 hosting the Company’s palladium-dominant “floor” mineralization and Horizon 3 hosting more gold-enriched material higher in the sequence. The VTM horizons occur as laterally continuous, oxide-bearing intervals interlayered with the precious-metal horizons, reflecting the intrusion’s distinctive combination of a fine-grained, alloy-hosted precious metals system overlying a coarser-grained iron-titanium-vanadium oxide system.

Site selection for all three major bulk samples was based on detailed geological mapping and the modelled surface outcrop expressions of the gold- and palladium-platinum-dominated horizons and the VTM intervals, cross-checked against historical geochemical assay data.

This included non-SK-1300-compliant historical assay data from three approximately 800-kilogram mini-bulk samples collected by blasting in 2003 from the same general area — one from the palladium-dominated horizon, returning historical assays of up to 4.34 g/t palladium and up to 0.54 g/t gold, and two from the gold-dominated horizon, returning historical assays of approximately 3.3 g/t gold and up to 0.5 g/t palladium — together with non-SK-1300-compliant historical channel-sample assay data across the horizons, with the most recent channel data dating from 2021. These historical figures are provided for geological context only, are non-S-K 1300 compliant, and were not relied upon in the Company’s current Mineral Resource Estimate.

In addition to the three major bulk-sample sites, four medium-sized bulk samples were collected from four further sites. These include two samples from the assumed outcropping, gold-dominated Horizon 5, weighing approximately 7.3 tons and 3.9 tons respectively, as well as two samples totaling approximately 4.3 tons from the southwest of the intrusion, representing the assumed outcropping palladium-platinum-dominated Horizon 0. These samples were collected to support variability studies, an essential step toward establishing a well-defined and stable metallurgical processing flowsheet.

As with the major sites, selection of these medium-sized sample locations was based on detailed mapping and modelled surface outcrop expressions, supported by historical channel-sample assay data across the horizons, with the most recent data from 2021.

The blasting program was carried out by an experienced blast crew from Greenlandic contractor Permagreen, working alongside Greenland Mines’ own geological and technical team, which also participated in collecting the blasted material into large heli-portable bulk bags. The bulk sample bags will be shipped later this season to GTK Mintec in Finland, where they will be used for large-scale test work and pilot-scale test work aimed at establishing an efficient and robust processing route for the gold-, palladium- and platinum-mineralized and VTM-bearing material at Skaergaard.

All bulk-sample sites were covered by new channel sampling for later reference assay work and also covered by detailed drone-based LiDAR digital elevation surveys and photography, enabling the Company to precisely map the volumes of material removed at each site.

Independent topic specialists in mine engineering, infrastructure planning, processing, and tailings and waste-rock management were also on site over recent weeks, working alongside the Greenland Mines team to assess site conditions, collect topic-specific data, and plan the next phase of technical work at Skaergaard.

Separately, the Company has successfully completed its ground-penetrating radar survey program at Skaergaard, generating detailed measurements of surface cover thickness and characteristics that will support ongoing infrastructure and mine engineering studies.


Sarfartoq: Camp Opened, Structural Mapping Underway, Second Year of Environmental Baseline Studies Completed

At Sarfartoq, Greenland Mines has opened and fully manned its exploration camp for the 2026 field season, marking the first full field program since the Company closed its acquisition of the project on September 1, 2026.

This work builds directly on the compelling project economics established by the Company’s Initial Assessment and closing of the Sarfartoq acquisition earlier this month, under which the ST1 deposit alone supports a high-case pre-tax net present value of approximately US$2.05 billion and a pre-tax internal rate of return of 118.6%, including Indicated and Inferred Mineral Resources, based on a nine-year mine life processing 12.2 million tons of material at a delivered head grade of 1.32% TREO. At 2025 consumption levels, Sarfartoq’s planned annual NdPr oxide production would represent approximately 34% of all NdPr oxide refined outside China, in every one of the Project’s nine scheduled operating years — underscoring why the Company is moving immediately from acquisition into the resource-growth and permitting work described below.

A consultancy team from WSP Denmark has been on site at Sarfartoq since early September conducting the second year of environmental baseline studies at Sarfartoq, building on the first year of baseline work completed in 2023. With this second year of fieldwork, Sarfartoq now has baseline data spanning the minimum two-year period required by Greenland’s Environmental Agency for Mineral Resource Activities.

The 2026 program includes terrestrial sampling of lichens across fifteen stations, including three reference stations, to characterize background metal levels; freshwater sampling at five stations across the Paradise Valley and Robinson Valley catchments, including collection of Arctic char; marine intertidal sampling of seaweed, mussels and sculpin near the planned port facility; servicing of the water-flow monitoring station installed in 2023 – which was found to be in good condition and with a data record from the last three years; and general botanical, mammal and bird surveys across the license area. All sampling is being conducted in accordance with protocols developed by the Danish Centre for Environment and Energy for the Greenland mineral resources environmental sample bank, and the work is being carried out with specific accommodation for protected zones in the area, including the Arnnangarnup Qoorua valley and adjacent goose moulting and breeding grounds.

Separately, a geological and structural mapping team led by consulting structural geologist Jeroen van Gool — who brings an extensive personal research history in the Sarfartoq area from previous work in Greenland — is now on site for a three-week program running through late September. The team includes consultants and experienced Greenland-focused geologists together with geology students from the University of Copenhagen.

The program is focused on producing a coherent, detailed geological and structural map of the northern part of the Sarfartoq license, an area that hosts both the prime ST1 resource zone and several additional rare earth exploration targets. The team is collecting rock samples for geochemical analysis, including portable XRF measurements in the field and laboratory whole-rock analysis, to help refine understanding of the grade and extent of known mineralization and to test for new, previously unrecognized occurrences of economic interest across the license.

The program also incorporates hand-held geophysical instrumentation and drone-based topographic mapping to generate detailed orthophotos and a digital elevation model of the mapped area, adding a further layer of high-resolution structural context ahead of the next phase of resource expansion work at Sarfartoq.

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and select midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

Forward-Looking Statements
 This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the Company’s field programs, exploration and metallurgical testwork plans, environmental permitting pathway, and expected timing of future technical studies at Skaergaard and Sarfartoq. These statements are based on current expectations and are subject to risks and uncertainties, including exploration, permitting, weather-related, logistical and financing risks. Field-measured tonnages referenced in this release are preliminary and subject to confirmation. Historical assay data referenced in this release relating to 2003 mini-bulk samples and historical channel sampling are historical in nature, have not been verified by a Qualified Person under SK-1300 or S-K 1300, and should not be relied upon as indicative of current or future mineral resources or reserves. The Initial Assessment for Sarfartoq referenced in this release is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have modifying factors applied to them that would enable them to be categorized as Mineral Reserves; there is no certainty that the results of the Initial Assessment will be realized, and no Mineral Reserves have been estimated for the Sarfartoq Project. Readers should refer to the Company’s SEC filings and technical report summaries for complete disclosure and risk factors.

Investor Contact and Corporate Communications:

ir@greenlandmines.com

Website: www.greenlandmines.com

Corporate Communications:

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Attachments

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.